Chest, Vol 100, 1254-1260, Copyright © 1991 by American College of Chest Physicians

ARTICLES

Duration of protection by inhaled salmeterol in exercise-induced asthma

SD Anderson, LT Rodwell, J Du Toit and IH Young
Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Beta-adrenoceptor agonists such as albuterol are very effective in preventing exercise-induced asthma (EIA) when they are given as an aerosol immediately before exercise. However, their duration of protection against EIA is usually less than 2 h. This may be due partly to their rapid clearance from the airways. Salmeterol is a highly lipophylic compound that is thought to bind to an exoreceptor near the beta-receptor. The objective of this study was to compare the protective effect of salmeterol with albuterol against EIA. Exercise was performed 0.5, 2.5, 4.5, and 6.5 hours after administration of the active drugs. Subjects attended the laboratory on four days within six weeks and cycled for 8 min breathing dry compressed air. We studied 17 asthmatic subjects (aged 19 to 49 years) with moderate to severe EIA. Salmeterol (50 micrograms) or albuterol (200 micrograms) was given from a metered dose inhaler via a spacer (Volumatic). On the control day, the mean work load +/- 1 SD was 174 +/- 47 W, ventilation (VE) was 77.9 percent +/- 11.2 percent of the target ventilation (60 percent maximum voluntary ventilation [MVV]), and heart rate was 170 +/- 14 beats per minute. This intensity was maintained for all tests. FEV1 was measured before and after exercise and was expressed as percent predicted and as percentage of the preexercise value (percentage of fall). Thirty minutes after treatment, both drugs were effective in inhibiting EIA-- percentage of fall in FEV1, 17 +/- 12 after salmeterol; percentage of fall in FEV1, 15 +/- 15 after albuterol. At 2.5, 4.5, and 6.5 hours, the reduction in FEV1 was significantly less (p less than 0.01) after salmeterol compared with albuterol. At 6.5 hours, the percentage of fall in FEV1 was 20 +/- 10 after salmeterol and 36 +/- 12 after albuterol. Salmeterol also had a more prolonged action as a bronchodilator and values for FEV1 were significantly higher compared with those on albuterol at 4.5 and 6.5 hours. At 6.5 hours, the FEV1 percent predicted was 96 +/- 10 after salmeterol and 84 +/- 12 after albuterol (p less than 0.01). We conclude that the extent of protection against EIA and the bronchodilation induced by both drugs was similar, but that salmeterol has a longer duration of action compared with albuterol. The reason for its superior duration of action may be due to a slower clearance of the drug from the airways.

This article has been cited by other articles:

				G. Philip, D. S. Pearlman, C. Villaran, C. Legrand, T. Loeys, R. B. Langdon, and T. F. Reiss Single-Dose Montelukast or Salmeterol as Protection Against Exercise-Induced Bronchoconstriction Chest, September 1, 2007; 132(3): 875 - 883. [Abstract] [Full Text] [PDF]

				A. Ek, L. Palmberg, B.-M. Sundblad, and K. Larsson Salmeterol Does Not Alter Increased Bronchial Responsiveness Caused by Organic Dust Exposure Chest, October 1, 2005; 128(4): 3038 - 3047. [Abstract] [Full Text] [PDF]

				K. Richter, S. Janicki, R.A. Jorres, and H. Magnussen Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline Eur. Respir. J., May 1, 2002; 19(5): 865 - 871. [Abstract] [Full Text] [PDF]

				B. Dahlen, P.M. O'Byrne, R.M. Watson, A. Roquet, F. Larsen, and M.D. Inman The reproducibility and sample size requirements of exercise-induced bronchoconstriction measurements Eur. Respir. J., April 1, 2001; 17(4): 581 - 588. [Abstract] [Full Text] [PDF]

				R. Crapo Guidelines for Methacholine and Exercise Challenge Testing---1999 . THIS OFFICIAL STATEMENT OF THE AMERICAN THORACIC SOCIETY WAS ADOPTED BY THE ATS BOARD OF DIRECTORS, JULY 1999 Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 309 - 329. [Full Text]

				E. A. Bronsky, D. S. Pearlman, B. F. Pobiner, C. Scott, Y. Wang, and E. Stahl Prevention of Exercise-induced Bronchospasm in Pediatric Asthma Patients: A Comparison of Two Salmeterol Powder Delivery Devices Pediatrics, September 1, 1999; 104(3): 501 - 506. [Abstract] [Full Text] [PDF]

				H. Milgrom and L. M. Taussig Keeping Children With Exercise-induced Asthma Active Pediatrics, September 1, 1999; 104 (3): e38 - e38. [Abstract] [Full Text] [PDF]

				J. D. BRANNAN, H. KOSKELA, S. D. ANDERSON, and N. CHEW Responsiveness to Mannitol in Asthmatic Subjects with Exercise- and Hyperventilation-induced Asthma Am. J. Respir. Crit. Care Med., October 1, 1998; 158(4): 1120 - 1126. [Abstract] [Full Text] [PDF]

				J. A. Nelson, L. Strauss, M. Skowronski, R. Ciufo, R. Novak, and E.R. McFadden Effect of Long-Term Salmeterol Treatment on Exercise-Induced Asthma N. Engl. J. Med., July 16, 1998; 339(3): 141 - 146. [Abstract] [Full Text] [PDF]

				S. D. ANDERSON, J. BRANNAN, J. SPRING, N. SPALDING, L. T. RODWELL, K. CHAN, I. GONDA, A. WALSH, and A. R. CLARK A New Method For Bronchial-provocation Testing in Asthmatic Subjects Using a Dry Powder of Mannitol Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 758 - 765. [Abstract] [Full Text] [PDF]